Complete Story
 

11/06/2018

A Message From Your Bulletin Sponsor

Merck

Merck

10/30/18 - FDA Approves Keytruda in Combination with Carboplatin and Either Paclitaxel or Nab-Paclitaxel for the First-Line Treatment of Patients with Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC).

READ MORE

 

10/22/18 - Merck's Keytruda Significantly Improved Overall Survival Compared to Standard of Care as Monotherapy and in Combination with Chemotherapy as First-Line Treatment for Patients with Recurrent or Metastatic Head and Neck Cancer

READ MORE

 

For More Recent Merck News Releases CLICK HERE

 

Printer-Friendly Version


Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message? Help us fix it! 
Report Broken Link